About this Research Topic
Atherosclerosis involves accumulation of fatty materials or plaques in the arteries. The buildup of plaque in the inner walls of arteries eventually causes thickening and hardening of the blood vessels. Pharmacological therapy for atherosclerosis involves the use of anti-thrombotic agents, thrombolytic agents, anti-dyslipidemia drugs and others to improve symptoms. Biologics have been useful in suppressing and activating components of atherosclerosis processes. For example, recent trials with anti-inflammatory antibodies have shown positive outcomes in atherosclerosis. Drug delivery systems such as nanoparticles for biologics delivery are also of interest for spatiotemporal delivery. Further discussion of the effects of biologics on the medicinal chemistry, drug delivery, vascular remodeling, lipid metabolism, endothelial and blood vessel functions and other cardiac risk factors is warranted.
Biologics such as siRNA, mRNA and DNA biomolecules, proteins including enzymes, antibodies and regulatory proteins are becoming preferred therapeutics of choice due to numerous advantages over small molecule drugs. For example, enzymes offer exquisite specificity and can work at catalytic outputs (i.e tPA as an anti-thrombolytic). As production, scale-up and testing of biological drugs progresses, the translation and commercialization of these specific and potent therapies will rise. In this Research Topic we would like to really address what are the hottest biological molecules and therapies out there currently for atherosclerosis therapy (i.e look at canakinumab in the CANTOS trial which was anti IL1-beta) and related anti-inflammatory proteins etc. Furthermore, biological drugs can suffer from poor bioavailability, short half-lives in vivo, protease damage, short shelf-life, costly production and immunogenic side-effects. We could also look at how PEGylation or nanoparticle aided delivery could help. Although key biologics such as as hydroxy-methyl-glutaryl CoA (HMG-CoA) reductase and protein convertase subtilisin/kexin type 9 inhibitors (PCSK9) have been exploited as pharmacological targets, the delivery of anti-atherogenic enzymes represents a relatively unexplored area. These are examples that this Research Topic could explore.
In this Research Topic we are interested in inviting contributions from physicians, scientists and researchers who are exploring both existing and pipeline novel biologics therapies for atherosclerosis.
This includes the potential use of peptide, protein, antibody, enzyme, nucleic acid based. In addition, we invite submissions on those modifying the biologics for atherosclerosis therapy which include surface modification or nanoparticle mediated delivery.
Submissions are welcome for the following article types: original research, review, mini-reviews, research protocol/method, opinion and hypothesis. We specially encourage clinicians who have tested novel biologics in athero trials to contribute.
Keywords: Pharmacology, Nanoparticles, Nanomedicine, Immunology, Blood, Artery, Plaque, Atherosclerosis, Biologics, Inflammation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.